Accelerator has announced the launch of Magnolia Neurosciences, a company developing a new class of neuroprotective therapies for patients.
Browsing: Cognitive/neurodegenerative disorders
Results from the Phase III TOLEDO study suggests that treatment of Parkinson’s with apomorphine increases periods of good motor control and reduces periods when Parkinson’s disease medications are ineffective.
In this interview, Marika tells us about her research on tissue clearing and imaging, including her opinion on what the biggest ‘hot topic’ in neurodegeneration is.
In a recent study, a scientist has revealed the development of a stem cell model to assess possible treatments for a rare nervous system disorder called Alexander disease.
Researchers have demonstrated encouraging results in the treatment of Alzheimer’s disease using the experimental drug BAN2401; this treatment significantly slowed clinical cognitive decline and lead to a size reduction in amyloid plaques.
Results from AAIC have revealed significant reductions in the risk of MCI and the combination of MCI and dementia through lowering systolic blood pressure.
Researchers at AAIC have reported new data on how the gut microbiome and lipid metabolism may influence Alzheimer’s and other brain diseases.
Research presented at AAIC 2018 highlights the challenges and successes of both drug and non-drug treatments for non-cognitive symptoms experienced by individuals with Alzheimer’s disease.